Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome

Lupus

Volumn 10, Issue 3, 2001, Pages 241-245

  Ruiz Irastorza, G ^a,b   Khamashta, M A ^c   Hughes, G R V ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL DE MENDARO   (Spain)

^c NONE

Author keywords

Antiphospholipid; Aspirin; Heparin; Miscarriage; Thrombosis; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; CLOPIDOGREL; COUMARIN DERIVATIVE; HEPARIN; TICLOPIDINE; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; BLEEDING; HUMAN; PREGNANCY DISORDER; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT ABORTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TREATMENT INDICATION;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLATELET AGGREGATION INHIBITORS;

EID: 0035049899     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301667789546     Document Type: Review

References (48)

1. The antiphospholipid syndrome: Ten years on
2. Management of thrombosis in the antiphospholipid syndrome
3. Guidelines on oral anticoagulation: Third edition
4. Warfarin and azathioprine: A drug interaction does exist
5. Potentiation of vitamin K antagonist by high-dose intravenous methyl-prednisolone
6. Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: Maternal and fetal complications and their management
7. Low-molecular-weight heparins
8. Thromboembolism
9. Unstable angina
10. Platelet-active drugs: The relationships among dose, effectiveness and side-effects
11. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) Trial
12. Stroke prevention
13. The antiplatelet effects of ticlopidine and clopidogrel
14. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
15. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
16. Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine
17. Update on antiplatelet therapy for stroke prevention
18. The anti-phospholipid antibody syndrome (Hughes' syndrome): Therapeutic aspects
19. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies
20. The management of thrombosis in the antiphospholipid-antibody syndrome
21. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
22. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment
23. Anticardiolipin antibodies predict early recurrence in thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy
24. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
25. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis
26. Antiphospholipid antibodies and venous thromboembolism
27. Guidelines on the investigation and management of the antiphospholipid syndrome
28. Guidelines
29. Audit of anticoagulant therapy
30. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia
31. Bleeding during antithrombotic therapy in patients with atrial fibrillation
32. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors
33. Thromboprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies
34. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
35. Safety of low-molecular-weight heparin in pregnancy: A systematic review
36. Maternal and fetal outcome in antiphospholipid syndrome pregnancies with a history of previous cerebral ischemia
37. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: Is warfarin preferable?
38. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomised trial comparing prednisone with low-dose heparin
39. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients
40. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss
41. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
42. A study of sixty pregnancies in patients with the antiphospholipid syndrome
43. Obstetric outcome in antiphospholipid syndrome
44. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomised controlled trial
45. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome
46. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
47. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
48. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience